Beyond 2 years, CABG with flow assessment was associated with a higher risk for new coronary angiography and new ...

Squeezed by insurers and middlemen, independent pharmacists such as Jolley find themselves on the front lines of a tariff ...

Risk for the autoimmune hair disorder was reduced by nearly 75% in patients on these treatments for psoriasis, finds a ...

The median age at symptom onset in the cohort was 55 years, ranging from 16 to 81 years. Data from patients’ initial ...

Swiss drugmaker Novartis will keep making medicines for malaria and leprosy, even if it does not get orders as normal amid ...

The latest annual TIME100 Health list, which debuted in 2024, highlights scientists, doctors, advocates, educators, and other ...

New Novartis data at ASCO and EHA showcase momentum of pioneering portfolio with promising pipeline: Basel Saturday, May 17, 2025, 11:00 Hrs [IST] Novartis will present data from ...

After decades of hype and setbacks, scientists have made impressive progress into tricking stem cells into repairing organs.

GlobalData analysts have tipped the global market for genomic therapies to balloon to almost $90 billion by 2030, driven by ...

Hospital groups are celebrating a federal judge’s initial ruling against pharmaceutical makers who contended a government ...

Novartis has agreed to buy Regulus Therapeutics for up to $1.7 billion, giving the Swiss drugmaker access to an experimental ...

Artificial intelligence is gaining ground in healthcare, and tech's biggest players are racing to stake their claims.